This Test Guideline describes an in vitro screen for chemical effects on steroidogenesis, specifically the production of 17ß-estradiol (E2) and testosterone (T). The human H295R adreno-carcinoma cell line, used for the assay, expresses genes that encode for all the key enzymes for steroidogenesis. After an acclimation period of 24 h in multi-well plates, cells are exposed for 48 h to seven concentrations of the test chemical in at least triplicate. Solvent and a known inhibitor and inducer of hormone production are run at a fixed concentration as negative and positive controls. At the end of the exposure period, cell viability in each well is analyzed. Concentrations of hormones in the medium can be measured using a variety of methods including commercially available hormone measurement kits and/or instrumental techniques such as liquid chromatography-mass spectrometry. Data are expressed as fold change relative to the solvent control and the Lowest-Observed-Effect-Concentration. If the assay is negative, the highest concentration tested is reported as the No-Observed-Effect-Concentration.
Test No. 456: H295R Steroidogenesis Assay
Report
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
Report
Assay for the Detection of Glucocorticoid Receptor Agonist and Antagonist Activity of Chemicals
2 July 202634 Pages -
Report
Assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins
2 July 202663 Pages -
Report
Assays addressing the Adverse Outcome Pathway Key Event on Keratinocyte activation
2 July 202698 Pages -
Report
In Vitro Skin Sensitisation assays addressing the Key Event on activation of dendritic cells on the Adverse Outcome Pathway for Skin Sensitisation
2 July 202694 Pages -
2 July 202651 Pages
Related publications
-
2 July 2026115 Pages
-
Report2 July 202632 Pages
-
2 July 202615 Pages
-
Report
Assay for the Detection of Glucocorticoid Receptor Agonist and Antagonist Activity of Chemicals
2 July 202634 Pages -
Report
Assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins
2 July 202663 Pages -
Report
Assays addressing the Adverse Outcome Pathway Key Event on Keratinocyte activation
2 July 202698 Pages